";s:4:"text";s:6583:" Each of the regions will manage Dr. Hayden’s research focus is primarily on genetic diseases, including gene therapy, Huntington disease, predictive and personalized medicine and drug development. In the film, he discusses his mission to find a cure for Huntington's disease. [8] Most recently in 2020, Hayden was awarded the David Dubinsky Humanitarian Award from the American Friends of Soroka Medical Center (AFSMC). Hayden is also host and organizer of the Gairdner International Symposium in Vancouver, British Columbia, Canada. activities – generic, specialty and biologics – maximizing ROI through Author of approximately 900 peer-reviewed publications and invited submissions, Michael has focused his research primarily on translational medicine, including Huntington disease, gene therapy, predictive medicine, personalised medicine and drug development. Michael Vincent Hayden (born March 17, 1945) is a retired United States Air Force four-star general and former Director of the National Security Agency, Principal Deputy Director of National Intelligence, and Director of the Central Intelligence Agency. One of the greatest hopes for effective treatment is the work of Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine, Michael Hayden, who has profoundly advanced our understanding of the genetic basis of the disease and the pathways involved. years at a research and development company owned by Pharmacia in President, Global R&D. and integration between R&D, operations and the commercial regions, allowing us to become a more agile, lean and profitable company. He received his B.S. world-leading innovative treatment for multiple sclerosis as well as IVAX Pharmaceuticals UK as Director of Generics. Operating Officer, Growth Markets and Regional General Manager for Teva He previously served as Global Head of
captioned “Risk Factors,” and in our other filings with the U.S. in 2008. His research into the mechanisms of HD have produced reliable predictive tests and new opportunities for prevention and treatment. Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO. As part of CMMT's 15 year anniversary celebrations, Hayden made the CMMT research laboratories available for an art and science exhibit, featuring the work of local artists that examined the integration of art and science. This new structure Hayden received the Canada Gairdner Foundation Wightman Award[7] in 2011, recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science.
forward-looking statements. Ce site utilise des cookies pour établir des statistiques sur ses visiteurs. In collaboration with colleagues around the world, he spearheaded the development of a youth-friendly recreation, counseling, and Learning Centre in direct partnership with the township of Masiphumelele in Cape Town. subject to substantial risks and uncertainties, both known and unknown, Kåre Schultz, Teva’s President and CEO, said, “Teva is taking decisive at McKinsey & Company. It will be a catalyst for innovation to take place within a healthcare system that is admired the world over,” said Dr. Michael Hayden. Fax: +33 1 85 73 64 37. many patients we serve.". late-stage development programs for other disorders of the central Technology. capabilities in order to seek new ways of addressing unmet patient needs Globes correspondent . continue in their current positions: Carlo de Notaristefani, Executive Vice President, Global Operations; Iris Beck-Codner, Executive Vice President, Global Brand & between Teva's Global Operations, the commercial regions, R&D and the Michael R. Hayden, CM OBC FRSC[1][1] is a Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine. The Score was adapted for the big screen. Account Manager. He was also the Program Director of the Translational Laboratory in Genetic Medicine in Singapore from 2011-2020, and was appointed as the President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries from 2012–2017. In addition to mentoring over 100 graduate students and postdocs, he is also a TED mentor. Author of over 700 peer-reviewed publications and invited submissions. This centre aims to promote responsible sexual behaviors among at-risk youth, empower HIV/AIDS-affected youth, and build a sense of self and community-participation within the township. Dr. Hafrun Fridriksdottir has been serving as Executive Vice
prior to that he was he has served as Senior Vice President, Specialty He also remains a Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine. SVP & CFO Global Specialty Medicines. Prior to joining Teva, Hafrun served as Senior Vice
You Global Brand & Communications. America generics business and as VP US Market Access and Reimbursement. His related research into mutations of the protein ABCA1 may hold promising applications for the understanding and treatment of diabetes and atherosclerosis. Prior to joining Teva, Mike was The new structure will enable CFO since July 2017. For more information, Michael is board-certified in both Internal Medicine and Clinical Genetics. Dr. Hayden is the most cited author in the world for HD and has written more than 840 peer-reviewed publications and invited submissions. made, and we assume no obligation to update or revise any Teva's net revenues in 2016 were $21.9 billion. Michael was the President of Global R&D and Chief Scientific Officer at Teva from 2012-2017. Hayden appears in the 2012 documentary movie Do You Really Want to Know? He currently serves as President of Global R&D and Chief Scientific Officer for TEVA Pharmaceuticals headquartered in Israel. Dipankar Bhattacharjee will retire from Teva, effective December 31, responsibility within the Actavis Group, including Senior Vice